Carl Icahn might be down, but he’s not out. The legendary activist investor, 87—who has seen the stock of his investment company,
Icahn Enterprises
plunge after an attack by short-seller Hindenburg Research and a possible federal probe—squares off on Thursday in a proxy fight at
Illumina
the dominant developer of gene-sequencing technology. Illumina has been mired in a messy attempt to buy its former unit, cancer screener Grail.
Saudi Arabia may wage oil ‘market share war’ against the US, reversing output cuts and unleashing a flood of supply, energy expert says
Saudi Arabia may flood the oil market next yearGetySaudi Arabia may wage a "market share war" against the US and...
